Evidence map›Paper›PMID 27528705›Full record

ArticleMolecular cancer research : MCR2016

A New Chromatin-Cytoskeleton Link in Cancer.

Amato J Giaccia

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer research : MCR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Amato J GiacciaDivision of Radiation and Cancer Biology, Department of Radiation Oncology, Stanford University Medical Center, Stanford, California. giaccia@stanford.edu.
Stanford University · US

Funding

Preclinical Testing of a Novel Therapy Targeting AXL in Advanced Kidney CancerR01CA198291 · NCI · STANFORD UNIVERSITY · PI RANKIN, ERINN B · 2016 to 2020
$2.4M
NCI NIH HHS R01 CA198291
6 · The paper itself

Abstract

The set domain containing 2 (SETD2) histone methyltransferase, located at 3p2, specifically trimethylates lysine 36 of histone H3 (H3K36me3). H3K36me3 is an active mark involved in transcriptional elongation and RNA processing and a key regulator of DNA repair. In fact, SETD2 is the only methyltransferase that "writes" the H3K36me3 mark. Recent results from Park and colleagues have found a new role for SETD2 in the methylation of K40 of α-tubulin. Loss of SETD2 abolishes methylation of K40 of α-tubulin and results in a dysfunctional mitotic spindle and abnormalities in cytokinesis. Thus, SETD2 links chromatin and cytoskeleton homeostasis through its methyltransferase activity. These studies have important implications on the role of SETD2 mutations in promoting genomic instability and tumor progression. Mol Cancer Res; 14(12); 1173-5. ©2016 AACR.

Indexed as

ChromatinCytoskeletonGenomic InstabilityHistone-Lysine N-MethyltransferaseHistonesHumansLysineMethylationMutationNeoplasm InvasivenessNeoplasm MetastasisNeoplasmsTubulinChromatinHistone-Lysine N-MethyltransferaseHistonesLysineSETD2 protein, humanTubulin

Identifiers

PMID27528705
PMCPMC5136307
OpenAlexW2510837245

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.